Toll-like receptor-4 modulation for cancer immunotherapy

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Awasthi, Shanjana ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer; Immune response; Immunomodulation; Inflammation; Toll like receptor 4

Indexed keywords

EID: 84905651464     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00328     Document Type: Article

References (74)

1. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A (1998) 95(2):588-93. doi:10.1073/pnas.95.2.588
2. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science (1998) 282(5396):2085-8. doi:10.1126/science.282.5396.2085
3. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett (2014) 345(2):196-202. doi:10.1016/j.canlet.2013.08.016
4. Xu JH, Fu JJ, Wang XL, Zhu JY, Ye XH, Chen SD. Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies. World J Gastroenterol (2013) 19(26):4234-41. doi:10.3748/wjg.v19.i26.4234
5. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett (2014) 345(2):235-41. doi:10.1016/j.canlet.2013.07.032
6. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol (2011) 2011:609579. doi:10.1155/2011/609579
7. Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 33(27):3485-95. doi:10.1038/onc.2013.302
8. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett (2009) 14(2):248-72. doi:10.2478/s11658-008-0048-z
9. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol (2006) 177(11):7980-9. doi:10.4049/jimmunol.177.11.7980
10. Kerepesi LA, Hess JA, Leon O, Nolan TJ, Schad GA, Abraham D. Toll-like receptor 4 (TLR4) is required for protective immunity to larval Strongyloides stercoralis in mice. Microbes Infect (2007) 9(1):28-34. doi:10.1016/j.micinf.2006.10.003
11. Imado T, Iwasaki T, Kitano S, Satake A, Kuroiwa T, Tsunemi S, et al. The protective role of host Toll-like receptor-4 in acute graft-versus-host disease. Transplantation (2010) 90(10):1063-70. doi:10.1097/TP.0b013e3181f86947
12. Jordan JM, Woods ME, Olano J, Walker DH. The absence of Toll-like receptor 4 signaling in C3H/HeJ mice predisposes them to overwhelming rickettsial infection and decreased protective Th1 responses. Infect Immun (2008) 76(8):3717-24. doi:10.1128/IAI.00311-08
13. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol (2001) 167(4):2250-6. doi:10.4049/jimmunol.167.4.2250
14. Nunez NG, Andreani V, Crespo MI, Nocera DA, Breser ML, Moron G, et al. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res (2012) 72(3):592-603. doi:10.1158/0008-5472.CAN-11-0534
15. Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med (2013) 45:e66. doi:10.1038/emm.2013.97
16. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 14(4):432-6. doi:10.1016/S0952-7915(02)00354-0
17. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine (2008) 42(2):145-51. doi:10.1016/j.cyto.2008.01.006
18. Chen YJ, Hsieh MY, Chang MY, Chen HC, Jan MS, Maa MC, et al. Eps8 protein facilitates phagocytosis by increasing TLR4-MyD88 protein interaction in lipopolysaccharide-stimulated macrophages. J Biol Chem (2012) 287(22):18806-19. doi:10.1074/jbc.M112.340935
19. Jain V, Halle A, Halmen KA, Lien E, Charrel-Dennis M, Ram S, et al. Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling. Blood (2008) 111(9):4637-45. doi:10.1182/blood-2007-11-126862
20. Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol (2006) 176(5):3070-9. doi:10.4049/jimmunol.176.5.3070
21. Underhill DM, Goodridge HS. Information processing during phagocytosis. Nat Rev Immunol (2012) 12(7):492-502. doi:10.1038/nri3244
22. Ni Gabhann J, Spence S, Wynne C, Smith S, Byrne JC, Coffey B, et al. Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-gamma production by natural killer cells. Clin Immunol (2012) 142(3):373-82. doi:10.1016/j.clim.2011.12.009
23. Wagner CS, Cresswell P. TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation. J Immunol (2012) 188(2):686-93. doi:10.4049/jimmunol.1102214
24. Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, et al. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood (2011) 117(24):6542-51. doi:10.1182/blood-2010-11-317966
25. Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, et al. Induction of TLR4-dependent CD8+ T cell immunity by murine beta-defensin2 fusion protein vaccines. Vaccine (2011) 29(18):3476-82. doi:10.1016/j.vaccine.2011.02.061
26. Siegemund S, Sauer K. Balancing pro- and anti-inflammatory TLR4 signaling. Nat Immunol (2012) 13(11):1031-3. doi:10.1038/ni.2452
27. Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther (2013) 6:1573-87. doi:10.2147/OTT.S50838
28. Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer (2008) 123(11):2644-50. doi:10.1002/ijc.23826
29. Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer (2013) 49(4):946-54. doi:10.1016/j.ejca.2012.09.022
30. Zou TH, Wang ZH, Fang JY. Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol (2013) 34(4):2441-50. doi:10.1007/s13277-013-0795-y
31. Huang L, Yuan K, Liu J, Ren X, Dong X, Tian W, et al. Polymorphisms of the TLR4 gene and risk of gastric cancer. Gene (2014) 537(1):46-50. doi:10.1016/j.gene.2013.12.030
32. Yang CX, Li CY, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast cancer. Tissue Antigens (2013) 81(4):221-6. doi:10.1111/tan.12096
33. Slattery ML, Herrick JS, Bondurant KL, Wolff RK. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer (2012) 130(12):2974-80. doi:10.1002/ijc.26314
34. Ehsan N, Murad S, Ashiq T, Mansoor MU, Gul S, Khalid S, et al. Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol (2013) 34(2):1053-9. doi:10.1007/s13277-013-0645-y
35. Wang L, Zhao Y, Qian J, Sun L, Lu Y, Li H, et al. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer (2013) 119(4):782-91. doi:10.1002/cncr.27792
36. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 65(12):5009-14. doi:10.1158/0008-5472.CAN-05-0784
37. Fu HY, Li C, Yang W, Gai XD, Jia T, Lei YM, et al. FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem (2013) 115(2):151-7. doi:10.1016/j.acthis.2012.06.002
38. Tang X, Zhu Y. TLR4 signaling promotes immune escape of human colon cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Oncol Res (2012) 20(1):15-24. doi:10.3727/096504012X13425470196092
39. Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, Espana C, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2011) 17(7):1464-73. doi:10.1002/ibd.21527
40. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol (2009) 100(8):725-31. doi:10.1002/jso.21392
41. Liao SJ, Zhou YH, Yuan Y, Li D, Wu FH, Wang Q, et al. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes alphavbeta3-mediated adhesion and invasive migration. Breast Cancer Res Treat (2012) 133(3):853-63. doi:10.1007/s10549-011-1844-0
42. Kelsh RM, McKeown-Longo PJ. Topographical changes in extracellular matrix: activation of TLR4 signaling and solid tumor progression. Trends Cancer Res (2013) 9:1-13.
43. Wang L, Zhu R, Huang Z, Li H, Zhu H. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci (2013) 58(8):2223-36. doi:10.1007/s10620-013-2745-3
44. Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis (2013) 4:e794. doi:10.1038/cddis.2013.334
45. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol (2009) 16(4):1043-50. doi:10.1245/s10434-009-0325-8
46. Naseemuddin M, Iqbal A, Nasti TH, Ghandhi JL, Kapadia AD, Yusuf N. Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int J Cancer (2012) 130(4):765-74. doi:10.1002/ijc.26100
47. Ahmed A, Wang JH, Redmond HP. Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol (2013) 20(Suppl 3):S389-96. doi:10.1245/s10434-012-2595-9
48. Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y, et al. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol (2014) 11(2):150-9. doi:10.1038/cmi.2013.59
49. Krieg AM. Toll-free vaccines? Nat Biotechnol (2007) 25(3):303-5. doi:10.1038/nbt0307-303
50. Ishizaka ST, Hawkins LD. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines (2007) 6(5):773-84. doi:10.1586/14760584.6.5.773
51. Dumonteil E, Bottazzi ME, Zhan B, Heffernan MJ, Jones K, Valenzuela JG, et al. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines (2012) 11(9):1043-55. doi:10.1586/erv.12.85
52. Piazza M, Rossini C, Della Fiorentina S, Pozzi C, Comelli F, Bettoni I, et al. Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. J Med Chem (2009) 52(4):1209-13. doi:10.1021/jm801333m
53. Hawkins LD, Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, et al. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther (2002) 300(2):655-61. doi:10.1124/jpet.300.2.655
54. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol (2013) 4:387. doi:10.3389/fimmu.2013.00387
55. Ledeboer A, Mahoney JH, Milligan ED, Martin D, Maier SF, Watkins LR. Spinal cord glia and interleukin-1 do not appear to mediate persistent allodynia induced by intramuscular acidic saline in rats. J Pain (2006) 7(10):757-67. doi:10.1016/j.jpain.2006.04.001
56. Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol (2007) 82(4):968-74. doi:10.1189/jlb.1206727
57. Hossain DM, Bhattacharyya S, Das T, Sa G. Curcumin: the multi-targeted therapy for cancer regression. Front Biosci (Schol Ed) (2012) 4:335-55. doi:10.2741/S272
58. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 267(1):133-64. doi:10.1016/j.canlet.2008.03.025
59. Zhu HT, Bian C, Yuan JC, Chu WH, Xiang X, Chen F, et al. Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway in experimental traumatic brain injury. J Neuroinflammation (2014) 11:59. doi:10.1186/1742-2094-11-59
60. Vilekar P, Awasthi S, Natarajan A, Anant S, Awasthi V. EF24 suppresses maturation and inflammatory response in dendritic cells. Int Immunol (2012) 24(7):455-64. doi:10.1093/intimm/dxr121
61. Ramani V, Madhusoodhanan R, Kosanke S, Awasthi S. A TLR4-interacting SPA4 peptide inhibits LPS-induced lung inflammation. Innate Immun (2013) 19(6):596-610. doi:10.1177/1753425912474851
62. Awasthi S, Brown K, King C, Awasthi V, Bondugula R. A toll-like receptor-4-interacting surfactant protein-A-derived peptide suppresses tumor necrosis factor-alpha release from mouse JAWS II dendritic cells. J Pharmacol Exp Ther (2011) 336(3):672-81. doi:10.1124/jpet.110.173765
63. Madhusoodhanan R, Moriasi C, Ramani V, Anant S, Awasthi S. A TLR4-interacting peptide inhibits lipopolysaccharide-stimulated inflammatory responses, migration and invasion of colon cancer SW480 cells. Oncoimmunology (2012) 1(9):1495-506. doi:10.4161/onci.22089
64. Panaro MA, Carofiglio V, Acquafredda A, Cavallo P, Cianciulli A. Anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF-kappaB activation in Caco-2 and SW480 human colon cancer cells. Br J Nutr (2012) 108(9):1623-32. doi:10.1017/S0007114511007227
65. Hodgkinson L. Digestive disease week 2010. Turning science into medicine - part 2. IDrugs (2010) 13(7):424-6.
66. Zhang J, Dou W, Zhang E, Sun A, Ding L, Wei X, et al. Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol (2014) 306(1):G27-36. doi:10.1152/ajpgi.00465.2012
67. Onier N, Hilpert S, Arnould L, Saint-Giorgio V, Davies JG, Jeannin JF, et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis (1999) 17(4):299-306. doi:10.1023/A:1006663017149
68. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol (2007) 563(1-3):1-17. doi:10.1016/j.ejphar.2007.02.018
69. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol (2010) 667:111-23. doi:10.1007/978-1-4419-1603-7_10
70. Gerard C, Baudson N, Ory T, Louahed J. Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLoS One (2014) 9(5):e94883. doi:10.1371/journal.pone.0094883
71. Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, et al. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunol Immunother (2012) 61(1):49-61. doi:10.1007/s00262-011-1090-7
72. Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res (2011) 17(12):3984-92. doi:10.1158/1078-0432.CCR-10-3262
73. Roy A, Singh MS, Upadhyay P, Bhaskar S. Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. Int J Pharm (2013) 445(1-2):171-80. doi:10.1016/j.ijpharm.2013.01.045
74. Akeda T, Yamanaka K, Kitagawa H, Kawabata E, Tsuda K, Kakeda M, et al. Intratumoral injection of OK-432 suppresses metastatic squamous cell carcinoma lesion inducing interferon-gamma and tumour necrosis factor-alpha. Clin Exp Dermatol (2012) 37(2):193-4. doi:10.1111/j.1365-2230.2011.04151.x